Wet, Dry AMD Require Different Methods of Treatment, Including Anti-VEGF: Julie Rosenthal, MD, MS

Why It Matters

AMD’s high prevalence drives substantial clinical and commercial demand for effective treatments, influencing ophthalmology practice and pharma pipelines. Advances in anti‑VEGF and emerging modalities could reshape patient outcomes and market dynamics.

Key Takeaways

• 19.8 million US adults affected by AMD (2019)
• Wet AMD treated with anti‑VEGF intravitreal injections
• Dry AMD management relies on AREDS antioxidant supplements
• Newer anti‑VEGF agents extend dosing intervals up to quarterly
• Gene, stem‑cell, and photobiomodulation therapies under investigation

Pulse Analysis

The growing burden of age‑related macular degeneration reflects both demographic shifts and lifestyle factors. While genetics and age are immutable risks, smoking, ultraviolet exposure, and diet modulate disease onset. Clinicians now emphasize early detection through routine retinal imaging, as subtle visual distortions—such as wavy lines or central scotomas—often precede irreversible damage. Public health campaigns during AMD Awareness Month aim to educate seniors and caregivers, encouraging timely ophthalmic evaluations that can differentiate between dry and wet phenotypes.

Therapeutic strategies have diverged sharply along the dry‑wet spectrum. Since 2005, anti‑vascular endothelial growth factor (anti‑VEGF) agents have become the cornerstone for wet AMD, delivering drug directly into the vitreous to suppress neovascular leakage. Recent formulations—faricimab, brolucizumab, and others—offer extended durability, reducing injection frequency from monthly to quarterly in many patients. Conversely, dry AMD lacks a pharmacologic cure; the Age‑Related Eye Disease Study (AREDS) supplements remain the only evidence‑based intervention to delay geographic atrophy. Ongoing trials explore complement inhibitors and neuroprotective agents, while gene‑editing and stem‑cell platforms promise regenerative solutions, albeit with regulatory and safety hurdles.

From a business perspective, the AMD market is poised for robust growth. Anti‑VEGF sales already exceed several billion dollars annually, and pipeline candidates could capture additional share by improving patient adherence through less frequent dosing. Parallel investments in diagnostic AI, tele‑ophthalmology, and home‑based vision monitoring are expanding the ecosystem. As emerging modalities mature, payers will evaluate cost‑effectiveness against long‑term vision preservation, shaping reimbursement frameworks. For providers, staying abreast of evolving treatment algorithms is essential to optimize outcomes and maintain competitive advantage in an increasingly data‑driven ophthalmic landscape.